Eastbourne Proposes Amylin Directors, Backs Icahn

Bloomberg – Hedge fund Eastbourne Capital Management LLC nominated five directors to the board of Amylin Pharmaceuticals Inc. and is supporting a slate put forward by investor Carl Icahn, after it “lost confidence” in leadership of the maker of the Byetta diabetes drug.

Eastbourne, which owns 12.5 percent of San Diego-based Amylin, said in a letter to management yesterday that the company’s board needs to be “significantly strengthened” after the stock fell almost 80 percent since Oct. 5, 2007. In November, Eastbourne said it was talking with Amylin about options including “a possible acquisition by a third party.”

Read Complete Article

About the HedgeCo News Team

The Hedge Fund News Team stays on top of breaking news in the Hedge Fund industry on an hourly basis. Signup to HedgeCo.Net to recieve Daily or Weekly news updates from our team.
This entry was posted in Syndicated and tagged , , , , , , , , , , , , , , , . Bookmark the permalink.

Comments are closed.